L-Dopa Prodrugs: An Overview of Trends for Improving Parkinsons Disease Treatment

Author(s): Antonio Di Stefano, Piera Sozio, Laura Serafina Cerasa, Antonio Iannitelli

Journal Name: Current Pharmaceutical Design

Volume 17 , Issue 32 , 2011

Become EABM
Become Reviewer
Call for Editor


L-Dopa is the mainstay of Parkinsons disease therapy; this drug is usually administered orally, but it is extensively metabolized in the gastrointestinal tract, so that relatively little arrives in the bloodstream as intact L-Dopa. The peripheral conversion of L-Dopa by amino acid decarboxylase to dopamine is responsible for the typical gastrointestinal and cardiovascular side effects. To minimize the conversion to dopamine outside the central nervous system, L-Dopa is usually given in combination with peripheral inhibitors of amino acid decarboxylase. In spite of that, other central nervous side effects such as dyskinesia, on-off phenomenon and end-of-dose deterioration still remain. The main factors responsible for the poor bioavailability are the drugs physical-chemical properties: low water and lipid solubility, resulting in unfavorable partition, and the high susceptibility to chemical and enzymatic degradation. Starting from these considerations the prodrug approach has been applied to L-Dopa in order to overcome its metabolism problems and to improve its bioavailability. The goal of this paper is to provide the reader with a critical overview on L-Dopa prodrugs here classified according to the nature of the main chemical modification on L-Dopa backbone that led to the formation of the desired derivative.

Keywords: Parkinson's disease, L-dopa, dopamine, prodrugs, codrugs, antiparkinson, dyskinesia, plasma, chronic oxidative stress, cell death

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [3482 - 3493]
Pages: 12
DOI: 10.2174/138161211798194495
Price: $65

Article Metrics

PDF: 51